Unknown

Dataset Information

0

Budesonide/Glycopyrronium/Formoterol: A Review in COPD.


ABSTRACT: Budesonide/glycopyrronium/formoterol (BREZTRI AEROSPHERE™; TRIXEO AEROSPHERE™) is an inhaled fixed-dose combination of the inhaled corticosteroid (ICS) budesonide, the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide and the long-acting β2-agonist (LABA) formoterol fumarate approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is delivered via a pressurized metered-dose Aerosphere inhaler and is formulated using co-suspension delivery technology. In two pivotal phase III trials of 24-52 weeks' duration, budesonide/glycopyrronium/formoterol reduced the rates of moderate/severe COPD exacerbations and improved lung function to a greater extent than budesonide/formoterol and/or glycopyrronium/formoterol. Budesonide/glycopyrronium/formoterol also demonstrated beneficial effects on dyspnoea, rescue medication requirements and health-related quality of life (HR-QOL), and reduced the risk of all-cause mortality. Budesonide/glycopyrronium/formoterol was generally well tolerated, with the tolerability profile being generally similar to that of the individual components. Budesonide/glycopyrronium/formoterol provides a useful and convenient option for the maintenance treatment of COPD, including for patients whose disease is inadequately controlled with dual ICS/LABA or LAMA/LABA therapy.

SUBMITTER: Heo YA 

PROVIDER: S-EPMC8384783 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9238100 | biostudies-literature
| S-EPMC8189959 | biostudies-literature
| S-EPMC3425335 | biostudies-literature
| S-EPMC6072677 | biostudies-other
| S-EPMC6383599 | biostudies-literature
| S-EPMC5182036 | biostudies-literature
| S-EPMC8240276 | biostudies-literature
| S-EPMC3873417 | biostudies-literature
| S-EPMC7184113 | biostudies-literature
| S-EPMC6585691 | biostudies-literature